March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
4 citations
,
July 2001 in “Journal of Cutaneous Medicine and Surgery” Tacrolimus is an effective treatment for several skin conditions with fewer side effects than cyclosporine.
15 citations
,
January 1998 in “Journal of Clinical Periodontology” Finasteride helps treat hair loss by blocking enzyme activity.
53 citations
,
October 2011 in “Psychoneuroendocrinology” Finasteride may help improve certain brain function issues linked to dopamine.
April 2023 in “Journal of Investigative Dermatology” Being allergic to linalool, a common fragrance ingredient, might contribute to developing frontal fibrosing alopecia.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
November 2022 in “Medicom Conference Report EADV 2022”
5 citations
,
August 2020 in “Stem Cell Research & Therapy” Using fat-derived stem cells with the drug meglumine antimoniate can help control skin disease and reduce parasites in mice with leishmaniasis.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
August 1993 in “Journal of dermatological science” 51 citations
,
May 2004 in “American journal of ophthalmology” Using topical prostaglandin F2α for glaucoma may cause loss of eyelash or eyebrow pigment.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
Cyclosporine is more effective than betamethasone for treating alopecia areata, despite mild side effects.
18 citations
,
July 2010 in “Journal of the American Academy of Dermatology” Folliculotropic mycosis fungoides can look like alopecia areata.
6 citations
,
January 2015 in “Journal of clinical & experimental dermatology research” The combination therapy may be more effective for mild alopecia areata, especially in patients with allergies.
10 citations
,
March 2016 in “Journal of The American Academy of Dermatology” Antiandrogenic drugs could be a good treatment option for frontal fibrosing alopecia.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.
The treatment showed limited success in repigmenting hair for vitiligo-associated leukotrichia.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
5 citations
,
March 2023 in “PubMed” Advanced therapy medicinal products show promise for vitiligo treatment with fewer side effects, but affordability is a challenge.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.